The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.

Abstract

OBJECTIVE:

Study results evaluating the efficacy and safety of clocortolone pivalate 0.1% cream in the treatment of adults, young children, and infants with inflammatory facial dermatoses are reported in this article. Clocortolone pivalate 0.1% cream, indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, is a mid-potency topical corticosteroid (Class 4) that has been studied and used extensively to treat a variety of corticosteroid-responsive inflammatory dermatoses, many of which often involve facial skin in both adults and children.

METHODS:

Clocortolone pivalate 0.01% cream was applied to affected facial skin in subjects presenting with seborrheic dermatitis, contact dermatitis, atopic dermatitis, or psoriasis. Application was completed three times daily for 21 days. Assessments of erythema, edema, transudation, lichenification, scaling, pruritus and/or pain were completed at baseline and Days 4, 7, 14, and 21. Overall therapeutic response was assessed at all follow-up visits. Forty-nine subjects were entered, ranging in age from 1 month to 88 years of age. Thirty-eight subjects completed the studies, with 11 subjects lost to follow-up after the first visit. Individuals between the ages of 13 and 19 years were pre-emptively excluded to avoid potential application of a corticosteroid to acne-affected or acne-prone skin.

RESULTS:

Treatment with clocortolone pivalate 0.1% cream resulted in decreases in erythema, edema, transudation, lichenification, scaling, and pruritus/pain in 76% of treated study subjects. The overall therapeutic response in approximately two-thirds of the subjects (68%) was rated as good to excellent. There were 7 adverse events noted over the course of the study that were judged to be related to treatment, all of which were cutaneous and localized to the site of application (acneiform eruptions, burning, and folliculitis).

CONCLUSION:

Clocortolone pivalate 0.1% cream was effective in relieving the signs and symptoms of corticosteroid-responsive inflammatory dermatoses involving facial skin, including seborrheic dermatitis, contact dermatitis, atopic dermatitis, and psoriasis. Overall, the safety profile was favorable and devoid of any treatment-related serious adverse events.

• Authors: Leon H Kircik, James Q Del Rosso
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 11 Issue 10 Pg. 1194-8 (Oct 2012) ISSN: 1545-9616 [Print] United States
• PMID: 23134984 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Glucocorticoids
• Fluocortolone
• clocortolone pivalate

Topics

• Adult
• Aged
• Aged, 80 and over
• Child
• Child, Preschool
• Dermatitis, Atopic (complications, drug therapy)
• Dermatitis, Contact (complications, drug therapy)
• Dermatitis, Seborrheic (complications, drug therapy)
• Edema (drug therapy, etiology)
• Erythema (drug therapy, etiology)
• Exudates and Transudates (drug effects)
• Facial Dermatoses (complications, drug therapy)
• Female
• Fluocortolone (adverse effects, analogs & derivatives, therapeutic use)
• Glucocorticoids (adverse effects, therapeutic use)
• Humans
• Infant
• Male
• Middle Aged
• Pain (drug therapy, etiology)
• Pruritus (drug therapy, etiology)
• Psoriasis (complications, drug therapy)
• Skin Cream
• Treatment Outcome
• Young Adult